Erschienen in:
19.01.2021 | ASO Author Reflections
ASO Author Reflections: PIPAC for Unresectable Colorectal Peritoneal Metastases
verfasst von:
Koen P. Rovers, MD, Robin J. Lurvink, MD, Simon W. Nienhuijs, MD, PhD, Ignace H. J. T. de Hingh, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 9/2021
Einloggen, um Zugang zu erhalten
Excerpt
Following encouraging preliminary safety, tolerability, and efficacy data,
1 pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been adopted as a treatment option for peritoneal metastases in a rapidly increasing number of hospitals, mainly in Europe.
1 Patients with unresectable colorectal peritoneal metastases (CPM) are offered 4- to 8-weekly PIPAC using 90–92 mg/m
2 of oxaliplatin (i.e. PIPAC-oxaliplatin), either as monotherapy or with concomitant systemic therapy.
2 Despite its rapid implementation worldwide, repetitive PIPAC-oxaliplatin has never been investigated as a palliative monotherapy for unresectable CPM in prospective clinical trials with prespecified eligibility criteria, interventions, and endpoints. As a first step to address this important evidence gap, the two-center, single-arm, phase II CRC-PIPAC trial
3 primarily aimed to assess the safety and antitumor activity of 6-weekly PIPAC-oxaliplatin monotherapy (92 mg/m
2) in 20 patients with isolated, unresectable, extensive CPM (including high-grade appendiceal mucinous neoplasms) undergoing a total of 59 procedures (range 1–6) in various lines of palliative treatment. …
